$33.76
6.12% yesterday
Nasdaq, Mar 11, 09:16 pm CET
ISIN
US60770K1079
Symbol
MRNA
Sector
Industry

Moderna Stock price

$33.76
+2.83 9.15% 1M
-45.75 57.54% 6M
-7.82 18.81% YTD
-78.22 69.85% 1Y
-104.44 75.57% 3Y
+10.15 42.99% 5Y
+15.16 81.51% 10Y
Nasdaq, Closing price Tue, Mar 11 2025
-2.20 6.12%
ISIN
US60770K1079
Symbol
MRNA
Sector
Industry

Key metrics

Market capitalization $13.03b
Enterprise Value $6.75b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.08
P/S ratio (TTM) P/S ratio 4.03
P/B ratio (TTM) P/B ratio 1.20
Revenue growth (TTM) Revenue growth -52.75%
Revenue (TTM) Revenue $3.24b
EBIT (operating result TTM) EBIT $-3.95b
Free Cash Flow (TTM) Free Cash Flow $-4.06b
Cash position $7.03b
EPS (TTM) EPS $-9.28
P/E forward negative
P/S forward 6.14
EV/Sales forward 3.18
Short interest 14.41%
Show more

Create a Free Account to create an Moderna alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Moderna Stock Analysis

Unlock Scores for Free

Analyst Opinions

26 Analysts have issued a Moderna forecast:

5x Buy
19%
17x Hold
65%
4x Sell
15%

Analyst Opinions

26 Analysts have issued a Moderna forecast:

Buy
19%
Hold
65%
Sell
15%

Financial data from Moderna

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
3,236 3,236
53% 53%
100%
- Direct Costs 1,653 1,653
69% 69%
51%
1,583 1,583
3% 3%
49%
- Selling and Administrative Expenses 985 985
6% 6%
30%
- Research and Development Expense 4,354 4,354
3% 3%
135%
-3,756 -3,756
4% 4%
-116%
- Depreciation and Amortization 189 189
69% 69%
6%
EBIT (Operating Income) EBIT -3,945 -3,945
7% 7%
-122%
Net Profit -3,561 -3,561
24% 24%
-110%

In millions USD.

Don't miss a Thing! We will send you all news about Moderna directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Moderna Stock News

Neutral
Seeking Alpha
about 13 hours ago
Moderna (NASDAQ:MRNA ) Barclays 27th Annual Global Healthcare Conference March 11, 2025 1:30 PM ET Company Participants Rose Loughlin - EVP of Research Lavina Talukdar - SVP, Head of IR Conference Call Participants Gena Wang - Barclays Gena Wang Good afternoon, everyone. My name is Gena Wang.
Neutral
24/7 Wall Street
about 20 hours ago
Things are heating up in the biotechnology space, with a flurry of recent initial public offerings and some notable insider purchases of the past week or so.
Positive
Barrons
3 days ago
The top executives of Moderna, Akamai, and FMC just bought stock on the open market. All three shares are in the red for 2025 after a tough 2024.
More Moderna News

Company Profile

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Head office United States
CEO Stéphane Bancel
Employees 5,800
Founded 2010
Website www.modernatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today